Logo image of JAGX

JAGUAR HEALTH INC (JAGX) Stock Fundamental Analysis

USA - NASDAQ:JAGX - US47010C8881 - Common Stock

2.12 USD
-0.15 (-6.61%)
Last: 10/16/2025, 8:00:03 PM
2.16 USD
+0.04 (+1.89%)
After Hours: 10/16/2025, 8:00:03 PM
Fundamental Rating

2

Overall JAGX gets a fundamental rating of 2 out of 10. We evaluated JAGX against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of JAGX have multiple concerns. JAGX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

JAGX had negative earnings in the past year.
JAGX had a negative operating cash flow in the past year.
JAGX had negative earnings in each of the past 5 years.
In the past 5 years JAGX always reported negative operating cash flow.
JAGX Yearly Net Income VS EBIT VS OCF VS FCFJAGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of JAGX (-84.21%) is worse than 73.85% of its industry peers.
With a Return On Equity value of -508.83%, JAGX is not doing good in the industry: 79.49% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -84.21%
ROE -508.83%
ROIC N/A
ROA(3y)-84.47%
ROA(5y)-88.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JAGX Yearly ROA, ROE, ROICJAGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

JAGX's Gross Margin of 81.88% is amongst the best of the industry. JAGX outperforms 85.13% of its industry peers.
In the last couple of years the Gross Margin of JAGX has grown nicely.
JAGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.72%
GM growth 5Y19.68%
JAGX Yearly Profit, Operating, Gross MarginsJAGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
JAGX has less shares outstanding than it did 1 year ago.
JAGX has less shares outstanding than it did 5 years ago.
The debt/assets ratio for JAGX has been reduced compared to a year ago.
JAGX Yearly Shares OutstandingJAGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
JAGX Yearly Total Debt VS Total AssetsJAGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -12.62, we must say that JAGX is in the distress zone and has some risk of bankruptcy.
JAGX has a Altman-Z score of -12.62. This is in the lower half of the industry: JAGX underperforms 75.90% of its industry peers.
A Debt/Equity ratio of 1.34 is on the high side and indicates that JAGX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.34, JAGX is not doing good in the industry: 77.44% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Altman-Z -12.62
ROIC/WACCN/A
WACC1.81%
JAGX Yearly LT Debt VS Equity VS FCFJAGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

JAGX has a Current Ratio of 0.95. This is a bad value and indicates that JAGX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.95, JAGX is doing worse than 83.59% of the companies in the same industry.
A Quick Ratio of 0.59 indicates that JAGX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.59, JAGX is doing worse than 87.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.59
JAGX Yearly Current Assets VS Current LiabilitesJAGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for JAGX have decreased strongly by -79.22% in the last year.
JAGX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.95%.
The Revenue has been growing by 15.14% on average over the past years. This is quite good.
EPS 1Y (TTM)-79.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.84%
Revenue 1Y (TTM)15.95%
Revenue growth 3Y39.19%
Revenue growth 5Y15.14%
Sales Q2Q%7.9%

3.2 Future

The Earnings Per Share is expected to grow by 40.54% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 118.46% on average over the next years. This is a very strong growth
EPS Next Y89.56%
EPS Next 2Y40.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year24.03%
Revenue Next 2Y26.98%
Revenue Next 3Y160.53%
Revenue Next 5Y118.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JAGX Yearly Revenue VS EstimatesJAGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
JAGX Yearly EPS VS EstimatesJAGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2019 2020 2021 2022 2023 2024 2025 2026 -200M -400M -600M -800M -1B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for JAGX. In the last year negative earnings were reported.
Also next year JAGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JAGX Price Earnings VS Forward Price EarningsJAGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JAGX Per share dataJAGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40 -50

4.3 Compensation for Growth

A more expensive valuation may be justified as JAGX's earnings are expected to grow with 40.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JAGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JAGUAR HEALTH INC

NASDAQ:JAGX (10/16/2025, 8:00:03 PM)

After market: 2.16 +0.04 (+1.89%)

2.12

-0.15 (-6.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners0.7%
Inst Owner Change0%
Ins Owners0.06%
Ins Owner Change0%
Market Cap4.60M
Analysts85.71
Price Target16.32 (669.81%)
Short Float %2.48%
Short Ratio0.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.02%
Min EPS beat(2)-41.08%
Max EPS beat(2)9.04%
EPS beat(4)3
Avg EPS beat(4)30.68%
Min EPS beat(4)-41.08%
Max EPS beat(4)98.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.44%
Min Revenue beat(2)-23.04%
Max Revenue beat(2)-11.83%
Revenue beat(4)1
Avg Revenue beat(4)-12.25%
Min Revenue beat(4)-23.04%
Max Revenue beat(4)8.52%
Revenue beat(8)2
Avg Revenue beat(8)-11.83%
Revenue beat(12)4
Avg Revenue beat(12)-6.94%
Revenue beat(16)5
Avg Revenue beat(16)-11.51%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.39
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-53.55
EYN/A
EPS(NY)-5.79
Fwd EYN/A
FCF(TTM)-12.85
FCFYN/A
OCF(TTM)-12.75
OCFYN/A
SpS5.44
BVpS3.68
TBVpS-4.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.21%
ROE -508.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.88%
FCFM N/A
ROA(3y)-84.47%
ROA(5y)-88.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.72%
GM growth 5Y19.68%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.95
Quick Ratio 0.59
Altman-Z -12.62
F-Score4
WACC1.81%
ROIC/WACCN/A
Cap/Depr(3y)32.24%
Cap/Depr(5y)19.49%
Cap/Sales(3y)5.33%
Cap/Sales(5y)3.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-79.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.84%
EPS Next Y89.56%
EPS Next 2Y40.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)15.95%
Revenue growth 3Y39.19%
Revenue growth 5Y15.14%
Sales Q2Q%7.9%
Revenue Next Year24.03%
Revenue Next 2Y26.98%
Revenue Next 3Y160.53%
Revenue Next 5Y118.46%
EBIT growth 1Y-4.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.49%
OCF growth 3YN/A
OCF growth 5YN/A